Literature DB >> 9224717

p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene.

R C Smith1, D Branellec, D H Gorski, K Guo, H Perlman, J F Dedieu, C Pastore, A Mahfoudi, P Denèfle, J M Isner, K Walsh.   

Abstract

gax, a diverged homeobox gene expressed in vascular smooth muscle cells (VSMCs), is down-regulated in vitro by mitogen stimulation and in vivo in response to vascular injury that leads to cellular proliferation. Recombinant Gax protein microinjected into VSMCs and fibroblasts inhibited the mitogen-induced entry into S-phase when introduced either during quiescence or early stages of G1. Overexpression of gax with a replication-defective adenovirus vector resulted in G0/G1 cell cycle arrest of VSMCs and fibroblasts. The gax-induced growth inhibition correlated with a p53-independent up-regulation of the cyclin-dependent kinase inhibitor p21. Gax overexpression also led to an association of p21 with cdk2 complexes and a decrease in cdk2 activity. Fibroblasts deficient in p21 were not susceptible to a reduction in cdk2 activity or growth inhibition by gax overexpression. Localized delivery of the virus to denuded rat carotid arteries significantly reduced neointima formation and luminal narrowing. These data indicate that gax overexpression can inhibit cell proliferation in a p21-dependent manner and can modulate injury-induced changes in vessel wall morphology that result from excessive cellular proliferation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224717     DOI: 10.1101/gad.11.13.1674

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  39 in total

1.  Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor.

Authors:  B Witzenbichler; Y Kureishi; Z Luo; A Le Roux; D Branellec; K Walsh
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival.

Authors:  Y Fujio; K Guo; T Mano; Y Mitsuuchi; J R Testa; K Walsh
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 3.  Gene therapy for restenosis.

Authors:  R C Smith; K Walsh
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

Review 4.  Role of homeobox genes in normal mammary gland development and breast tumorigenesis.

Authors:  Hexin Chen; Saraswati Sukumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

5.  Regulation of vascular smooth muscle cell growth: targeting the final common pathway.

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-01       Impact factor: 8.311

6.  MEOX2 regulates nuclear factor-kappaB activity in vascular endothelial cells through interactions with p65 and IkappaBbeta.

Authors:  Yun Chen; Arnold B Rabson; David H Gorski
Journal:  Cardiovasc Res       Date:  2010-04-26       Impact factor: 10.787

7.  Growth arrest-specific homeobox is associated with poor survival in patients with hepatocellular carcinoma.

Authors:  Peng Zhou; Zhi Chen; Rui-Min Chang; Wei Jiang; Lie-Lin Wu; Zhi-Ming Wang
Journal:  Med Oncol       Date:  2012-05-27       Impact factor: 3.064

8.  Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5.

Authors:  Yun Chen; David H Gorski
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

Review 9.  Transcriptional control of the cell cycle in mammary gland development and tumorigenesis.

Authors:  Ricardo D Coletta; Paul Jedlicka; Arthur Gutierrez-Hartmann; Heide L Ford
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

10.  The homeobox gene GAX activates p21WAF1/CIP1 expression in vascular endothelial cells through direct interaction with upstream AT-rich sequences.

Authors:  Yun Chen; Alejandro D Leal; Sejal Patel; David H Gorski
Journal:  J Biol Chem       Date:  2006-10-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.